Liquidata Share/ETF/Trust Analysis
Portfolio Holdings Detail for ISIN IE00BF4RFH31
| Stock Name / Fund | iShares MSCI World Small Cap UCITS ETF USD (Acc) |
| Issuer | Blackrock |
| Entity holding fund | iShares III Public Limited Company |
| Entity Type | Umbrella investment company with variable capital and having segregated liability between its funds |
| Entity LEI | 549300PZLRJB7M8H1057 |
| ETF Ticker | WSML(USD) LSE |
| ETF Ticker | WLDS(GBP) LSE |
| ETF Ticker | IUSN(EUR) F |
| ETF Ticker | IUSN.DE(EUR) CXE |
| ETF Ticker | WLDS.LS(GBP) CXE |
| ETF Ticker | WSML.LS(USD) CXE |
| ETF Ticker | WSML.L(GBP) LSE |
| ETF Ticker | WLDS.L(GBP) LSE |
Holdings detail for IMVT
| Stock Name | Immunovant Inc |
| Ticker | IMVT(USD) NASDAQ |
| TYPE | Common Stock |
| Country | USA |
| ISIN | US45258J1025 |
Show aggregate IMVT holdings
News associated with IMVT
- Immunovant, Inc. (NASDAQ:IMVT) Given Consensus Recommendation of “Moderate Buy” by Brokerages
- Immunovant, Inc. (NASDAQ:IMVT – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the twelve ratings firms that are covering the company, Marketbeat Ratings reports. Three research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating on the […] - 2025-08-26 04:26:49
- Bank of America Lowers Immunovant (NASDAQ:IMVT) Price Target to $30.00
- Immunovant (NASDAQ:IMVT – Get Free Report) had its price objective reduced by equities research analysts at Bank of America from $33.00 to $30.00 in a report released on Tuesday,Benzinga reports. The firm currently has a “buy” rating on the stock. Bank of America‘s price objective would suggest a potential upside of 88.80% from the stock’s […] - 2025-08-14 03:07:05
- Immunovant Posts 34% R&D Jump in Q1
- Key Points- Immunovant’s net loss widened to $0.71 per share (GAAP) in Q1 FY2026 as expenses rose with pipeline expansion. - 2025-08-11 08:27:59
- Immunovant, Inc. (NASDAQ:IMVT) Receives $36.40 Average Price Target from Analysts
- Immunovant, Inc. (NASDAQ:IMVT – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the eleven ratings firms that are presently covering the stock, Marketbeat.com reports. Three analysts have rated the stock with a hold recommendation, seven have issued a buy recommendation and one has assigned a strong buy recommendation to the […] - 2025-08-04 02:42:53
- Analysts Set Immunovant, Inc. (NASDAQ:IMVT) Target Price at $38.33
- Immunovant, Inc. (NASDAQ:IMVT – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the ten brokerages that are covering the firm, Marketbeat reports. Two analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. The […] - 2025-07-10 02:50:51
- Immunovant, Inc. (NASDAQ:IMVT) Receives Consensus Rating of “Moderate Buy” from Brokerages
- Immunovant, Inc. (NASDAQ:IMVT – Get Free Report) has earned an average recommendation of “Moderate Buy” from the ten analysts that are currently covering the stock, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the […] - 2025-06-12 05:18:48
- How The Pieces Add Up: SCHK Headed For $32
- Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-06-05 07:23:06
- ProShare Advisors LLC Buys 3,681 Shares of Immunovant, Inc. (NASDAQ:IMVT)
- ProShare Advisors LLC boosted its position in Immunovant, Inc. (NASDAQ:IMVT – Free Report) by 18.8% during the 4th quarter, Holdings Channel.com reports. The firm owned 23,300 shares of the company’s stock after purchasing an additional 3,681 shares during the period. ProShare Advisors LLC’s holdings in Immunovant were worth $577,000 as of its most recent filing […] - 2025-05-26 05:18:59
- Immunovant, Inc. (NASDAQ:IMVT) Receives Average Recommendation of “Moderate Buy” from Brokerages
- Immunovant, Inc. (NASDAQ:IMVT – Get Free Report) has been given a consensus rating of “Moderate Buy” by the ten ratings firms that are covering the firm, Marketbeat reports. Two analysts have rated the stock with a hold recommendation, seven have given a buy recommendation and one has given a strong buy recommendation to the company. […] - 2025-05-23 05:00:51
- Immunovant, Inc. (NASDAQ:IMVT) Shares Purchased by D. E. Shaw & Co. Inc.
- D. E. Shaw & Co. Inc. increased its holdings in shares of Immunovant, Inc. (NASDAQ:IMVT – Free Report) by 8.4% in the fourth quarter, Holdings Channel reports. The firm owned 67,669 shares of the company’s stock after buying an additional 5,234 shares during the quarter. D. E. Shaw & Co. Inc.’s holdings in Immunovant were […] - 2025-05-22 04:48:46
- The Manufacturers Life Insurance Company Sells 772 Shares of Immunovant, Inc. (NASDAQ:IMVT)
- The Manufacturers Life Insurance Company lowered its stake in shares of Immunovant, Inc. (NASDAQ:IMVT – Free Report) by 2.1% during the fourth quarter, HoldingsChannel reports. The firm owned 35,908 shares of the company’s stock after selling 772 shares during the quarter. The Manufacturers Life Insurance Company’s holdings in Immunovant were worth $889,000 as of its […] - 2025-05-15 04:45:06
- Invesco Ltd. Lowers Holdings in Immunovant, Inc. (NASDAQ:IMVT)
- Invesco Ltd. reduced its position in shares of Immunovant, Inc. (NASDAQ:IMVT – Free Report) by 15.2% in the fourth quarter, Holdings Channel reports. The firm owned 504,032 shares of the company’s stock after selling 90,210 shares during the period. Invesco Ltd.’s holdings in Immunovant were worth $12,485,000 at the end of the most recent reporting […] - 2025-04-22 04:57:06
- Geode Capital Management LLC Purchases 4,094 Shares of Immunovant, Inc. (NASDAQ:IMVT)
- Geode Capital Management LLC grew its position in Immunovant, Inc. (NASDAQ:IMVT – Free Report) by 0.3% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,515,020 shares of the company’s stock after acquiring an additional 4,094 shares during the quarter. Geode […] - 2025-04-16 04:39:00
- Norges Bank Buys Shares of 637,947 Immunovant, Inc. (NASDAQ:IMVT)
- Norges Bank purchased a new position in shares of Immunovant, Inc. (NASDAQ:IMVT – Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 637,947 shares of the company’s stock, valued at approximately $15,802,000. A number of other large investors have also […] - 2025-04-08 04:46:59
- Peek Under The Hood: DFAC Has 28% Upside
- Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-04-04 08:47:40
- Teacher Retirement System of Texas Acquires 2,373 Shares of Immunovant, Inc. (NASDAQ:IMVT)
- Teacher Retirement System of Texas increased its holdings in shares of Immunovant, Inc. (NASDAQ:IMVT – Free Report) by 18.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 15,203 shares of the company’s stock after acquiring an additional 2,373 shares during the quarter. […] - 2025-04-01 04:44:44
- Brokerages Set Immunovant, Inc. (NASDAQ:IMVT) Price Target at $41.00
- Shares of Immunovant, Inc. (NASDAQ:IMVT – Get Free Report) have been given a consensus recommendation of “Buy” by the ten analysts that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation, eight have issued a buy recommendation and one has given a strong buy recommendation to the […] - 2025-04-01 02:40:43
- HC Wainwright Reiterates “Buy” Rating for Immunovant (NASDAQ:IMVT)
- Immunovant (NASDAQ:IMVT – Get Free Report)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a research note issued to investors on Wednesday,Benzinga reports. They currently have a $51.00 price objective on the stock. HC Wainwright’s target price indicates a potential upside of 159.01% from the company’s previous close. Several other […] - 2025-03-21 04:42:50
- Guggenheim Reaffirms Buy Rating for Immunovant (NASDAQ:IMVT)
- Guggenheim reiterated their buy rating on shares of Immunovant (NASDAQ:IMVT – Free Report) in a report issued on Monday morning,Benzinga reports. A number of other brokerages have also issued reports on IMVT. Cantor Fitzgerald upgraded shares of Immunovant to a “strong-buy” rating in a research report on Tuesday, March 4th. Jefferies Financial Group assumed coverage […] - 2025-03-11 04:40:47
- Immunovant, Inc. (NASDAQ:IMVT) Receives $43.55 Consensus Target Price from Analysts
- Shares of Immunovant, Inc. (NASDAQ:IMVT – Get Free Report) have received an average recommendation of “Moderate Buy” from the thirteen ratings firms that are currently covering the company, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy […] - 2025-03-07 04:43:06
- Immunovant (NASDAQ:IMVT) Coverage Initiated at Jefferies Financial Group
- Equities researchers at Jefferies Financial Group began coverage on shares of Immunovant (NASDAQ:IMVT – Get Free Report) in a research report issued to clients and investors on Monday, MarketBeat.com reports. The brokerage set a “hold” rating and a $20.00 price target on the stock. Jefferies Financial Group’s price objective suggests a potential upside of 8.17% […] - 2025-03-05 05:04:58
- Comparing Immunovant (NASDAQ:IMVT) & OKYO Pharma (NASDAQ:OKYO)
- Immunovant (NASDAQ:IMVT – Get Free Report) and OKYO Pharma (NASDAQ:OKYO – Get Free Report) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, risk, dividends and institutional ownership. Profitability This table compares Immunovant and OKYO Pharma’s net […] - 2025-03-05 04:20:53
- Immunovant, Inc. (NASDAQ:IMVT) Shares Sold by Principal Financial Group Inc.
- Principal Financial Group Inc. trimmed its holdings in shares of Immunovant, Inc. (NASDAQ:IMVT – Free Report) by 16.7% in the 4th quarter, HoldingsChannel.com reports. The fund owned 791,863 shares of the company’s stock after selling 159,261 shares during the quarter. Principal Financial Group Inc.’s holdings in Immunovant were worth $19,614,000 as of its most recent […] - 2025-02-25 06:48:54
- Guggenheim Cuts Immunovant (NASDAQ:IMVT) Price Target to $44.00
- Immunovant (NASDAQ:IMVT – Get Free Report) had its price target dropped by equities researchers at Guggenheim from $46.00 to $44.00 in a research report issued to clients and investors on Monday,Benzinga reports. The firm presently has a “buy” rating on the stock. Guggenheim’s price objective would indicate a potential upside of 127.51% from the company’s […] - 2025-02-12 06:46:57
- Immunovant, Inc. (NASDAQ:IMVT) Receives $47.00 Consensus PT from Brokerages
- Shares of Immunovant, Inc. (NASDAQ:IMVT – Get Free Report) have been assigned an average recommendation of “Buy” from the twelve ratings firms that are presently covering the company, MarketBeat reports. One research analyst has rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating […] - 2025-02-12 06:09:06
- Immunovant (NASDAQ:IMVT) Sets New 1-Year Low on Disappointing Earnings
- Immunovant, Inc. (NASDAQ:IMVT – Get Free Report) shares hit a new 52-week low during trading on Monday following a weaker than expected earnings announcement. The stock traded as low as $19.82 and last traded at $19.60, with a volume of 702620 shares trading hands. The stock had previously closed at $20.41. The company reported ($0.76) […] - 2025-02-12 04:14:58
- Immunovant, Inc. (NASDAQ:IMVT) Shares Bought by KBC Group NV
- KBC Group NV boosted its position in shares of Immunovant, Inc. (NASDAQ:IMVT – Free Report) by 60.1% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 3,099 shares of the company’s stock after buying an additional 1,163 shares during the quarter. KBC Group NV’s […] - 2025-02-10 16:30:58
iShares MSCI World Small Cap UCITS ETF USD (Acc) IMVT holdings
| Date | Number of IMVT Shares Held | Base Market Value of IMVT Shares | Local Market Value of IMVT Shares | Change in IMVT Shares Held | Change in IMVT Base Value | Current Price per IMVT Share Held | Previous Price per IMVT Share Held |
|---|
| 2025-10-15 (Wednesday) | 52,867 | USD 947,905 | USD 947,905 | | | | |
| 2025-10-10 (Friday) | 52,537 | USD 894,705 | USD 894,705 | | | | |
| 2025-10-08 (Wednesday) | 52,537 | USD 844,532 | USD 844,532 | | | | |
| 2025-10-07 (Tuesday) | 52,537 | USD 846,371 | USD 846,371 | 222 | USD -19,442 | USD 16.11 | USD 16.55 |
| 2025-10-06 (Monday) | 52,315 | USD 865,813 | USD 865,813 | 0 | USD -18,311 | USD 16.55 | USD 16.9 |
| 2025-10-03 (Friday) | 52,315 | USD 884,124 | USD 884,124 | 0 | USD 8,894 | USD 16.9 | USD 16.73 |
| 2025-10-02 (Thursday) | 52,315 | USD 875,230 | USD 875,230 | 0 | USD 20,403 | USD 16.73 | USD 16.34 |
| 2025-10-01 (Wednesday) | 52,315 | USD 854,827 | USD 854,827 | 0 | USD 11,509 | USD 16.34 | USD 16.12 |
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdingsShare Trades of IMVT by Blackrock for IE00BF4RFH31
Show aggregate share trades of IMVT| Date | Action | Quantity | Market High | Market Low | Likely Trade Price | Likely Trade Value (Profit/Loss) | Average Price previous trades |
|---|
| 2025-10-07 | BUY | 222 | | | 16.110* | | 20.28 |
| 2025-09-08 | SELL | -444 | | | 16.370* | | 20.48 Profit of 9,092 on sale |
| 2025-08-15 | BUY | 220 | | | 15.220* | | 20.51 |
| 2025-08-07 | BUY | 654 | | | 15.730* | | 20.56 |
| 2025-07-29 | BUY | 218 | | | 16.650* | | 20.70 |
| 2025-07-14 | BUY | 440 | | | 18.590* | | 20.81 |
| 2025-06-30 | BUY | 440 | | | 16.000* | | 20.97 |
| 2025-06-25 | BUY | 660 | | | 15.750* | | 21.07 |
| 2025-06-20 | SELL | -111 | | | 15.800* | | 21.17 Profit of 2,350 on sale |
| 2025-06-12 | SELL | -888 | | | 15.940* | | 21.39 Profit of 18,994 on sale |
| 2025-06-02 | BUY | 336 | | | 15.410* | | 21.69 |
| 2025-05-28 | BUY | 224 | | | 14.100* | | 21.85 |
| 2025-05-14 | BUY | 112 | | | 13.780* | | 22.43 |
| 2025-05-13 | BUY | 222 | | | 14.020* | | 22.50 |
| 2025-05-07 | BUY | 333 | | | 13.880* | | 22.77 |
| 2025-04-28 | BUY | 111 | | | 15.420* | | 23.21 |
| 2025-04-16 | BUY | 1,443 | | | 14.840* | | 23.84 |
| 2025-04-14 | BUY | 222 | | | 15.430* | | 24.00 |
| 2025-04-08 | SELL | -222 | | | 13.310* | | 24.37 Profit of 5,411 on sale |
| 2025-04-04 | SELL | -224 | | | 14.580* | | 24.57 Profit of 5,504 on sale |
| 2025-03-28 | BUY | 1,110 | | | 18.370* | | 24.89 |
| 2025-03-24 | BUY | 12,331 | | | 19.440* | | 25.17 |
| 2025-03-12 | SELL | -164 | | | 19.120* | | 25.73 Profit of 4,219 on sale |
| 2025-03-04 | SELL | -164 | | | 18.490* | | 26.12 Profit of 4,283 on sale |
| 2025-02-26 | SELL | -328 | | | 20.080* | | 26.45 Profit of 8,676 on sale |
| 2025-02-13 | BUY | 84 | | | 19.860* | | 27.27 |
| 2025-02-12 | BUY | 336 | | | 19.220* | | 27.39 |
| 2025-01-27 | BUY | 81 | | | 22.400* | | 28.81 |
| 2025-01-23 | BUY | 81 | | | 23.400* | | 29.03 |
| 2024-12-09 | BUY | 2,916 | | | 28.700* | | 29.15 |
| 2024-12-04 | BUY | 162 | | | 28.520* | | 29.20 |
| 2024-12-03 | BUY | 243 | | | 28.220* | | 29.22 |
| 2024-11-19 | BUY | 486 | | | 25.220* | | 29.95 |
| 2024-11-18 | BUY | 162 | | | 25.510* | | 30.09 |
| 2024-11-12 | BUY | 320 | | | 29.270* | | 30.12 |
| 2024-11-11 | BUY | 80 | | | 31.140* | | 30.04 |
| 2024-11-11 | BUY | 80 | | | 31.140* | | 30.04 |
| 2024-11-07 | BUY | 395 | | | 29.930* | | 30.00 |
| 2024-11-07 | BUY | 395 | | | 29.930* | | 30.00 |
| 2024-10-23 | BUY | 158 | | | 30.020* | | 29.49 |
| 2024-10-23 | BUY | 158 | | | 30.020* | | 29.49 |
Market high and low price is on the date. * (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection
The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close
Shorting History of IMVT
| Date | Shorted Volume | Short Exempt Volume | Total Shares Traded | % Shorted |
|---|
| 2025-09-19 | 237,771 | 0 | 521,187 | 45.6% |
| 2025-09-18 | 226,775 | 0 | 506,190 | 44.8% |
| 2025-09-17 | 318,308 | 0 | 572,777 | 55.6% |
| 2025-09-16 | 284,018 | 0 | 524,501 | 54.2% |
| 2025-09-15 | 298,530 | 184 | 553,288 | 54.0% |
| 2025-09-12 | 266,121 | 411 | 919,716 | 28.9% |
| 2025-09-11 | 239,307 | 8,320 | 608,146 | 39.4% |
| 2025-09-10 | 226,067 | 533 | 740,817 | 30.5% |
| 2025-09-09 | 206,013 | 0 | 593,070 | 34.7% |
| 2025-09-08 | 386,759 | 0 | 554,652 | 69.7% |
| 2025-09-05 | 275,617 | 5,000 | 968,660 | 28.5% |
| 2025-09-04 | 462,842 | 4,880 | 766,807 | 60.4% |
| 2025-09-03 | 1,074,129 | 22,370 | 2,021,541 | 53.1% |
| 2025-09-02 | 219,699 | 0 | 617,991 | 35.6% |
| 2025-08-29 | 104,250 | 0 | 282,354 | 36.9% |
| 2025-08-28 | 83,203 | 190 | 219,044 | 38.0% |
| 2025-08-27 | 117,872 | 143 | 563,634 | 20.9% |
| 2025-08-26 | 86,125 | 0 | 351,038 | 24.5% |
| 2025-08-25 | 114,242 | 0 | 393,226 | 29.1% |
| 2025-08-22 | 81,723 | 0 | 567,871 | 14.4% |
| 2025-08-21 | 86,392 | 0 | 519,866 | 16.6% |
| 2025-08-20 | 107,531 | 100 | 642,292 | 16.7% |
| 2025-08-19 | 105,490 | 0 | 456,267 | 23.1% |
| 2025-08-18 | 105,745 | 501 | 404,902 | 26.1% |
| 2025-08-15 | 95,384 | 1,200 | 1,001,483 | 9.5% |
| 2025-08-14 | 106,216 | 0 | 467,028 | 22.7% |
| 2025-08-13 | 157,418 | 3,846 | 443,391 | 35.5% |
| 2025-08-12 | 351,306 | 0 | 413,333 | 85.0% |
| 2025-08-11 | 264,054 | 0 | 468,922 | 56.3% |
| 2025-08-08 | 166,099 | 324 | 243,990 | 68.1% |
| 2025-08-07 | 103,572 | 8 | 177,672 | 58.3% |
| 2025-08-06 | 171,455 | 66 | 250,718 | 68.4% |
| 2025-08-05 | 174,569 | 0 | 295,997 | 59.0% |
| 2025-08-04 | 125,814 | 0 | 208,570 | 60.3% |
| 2025-08-01 | 325,671 | 223 | 565,813 | 57.6% |
| 2025-07-31 | 182,552 | 213 | 394,833 | 46.2% |
| 2025-07-30 | 199,331 | 0 | 404,854 | 49.2% |
| 2025-07-29 | 186,864 | 6,654 | 505,167 | 37.0% |
| 2025-07-28 | 242,810 | 16,158 | 605,008 | 40.1% |
| 2025-07-25 | 729,813 | 11,659 | 1,679,637 | 43.5% |
| 2025-07-24 | 226,015 | 38,604 | 388,761 | 58.1% |
| 2025-07-23 | 284,309 | 69,677 | 444,147 | 64.0% |
| 2025-07-22 | 160,560 | 33,025 | 259,862 | 61.8% |
| 2025-07-21 | 130,773 | 0 | 240,834 | 54.3% |
| 2025-07-18 | 169,609 | 0 | 264,619 | 64.1% |
The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.
Back to Listing
Disclaimer
All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.